Education
About Us
Working with TipRanks
Follow Us
Salarius Pharmaceuticals Inc (SLRX)
NASDAQ:SLRX
RESEARCH TOOLSreports
SLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $7.20
Previous CloseN/A
Volume13.28K
Average Volume (3M)4.17M
Market Cap
$3.82M
Enterprise Value-$431.55K
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$112.23K
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,645,594
10 Day Avg. Volume12,063,200
30 Day Avg. Volume4,165,749
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit390.19
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Salarius Pharmaceuticals News
SLRX FAQ
What was Salarius Pharmaceuticals Inc’s price range in the past 12 months?
Salarius Pharmaceuticals Inc lowest stock price was $0.45 and its highest was $7.20 in the past 12 months.
What is Salarius Pharmaceuticals Inc’s market cap?
Salarius Pharmaceuticals Inc’s market cap is $3.82M.
When is Salarius Pharmaceuticals Inc’s upcoming earnings report date?
Salarius Pharmaceuticals Inc’s upcoming earnings report date is Aug 06, 2025 which is 6 days ago.
How were Salarius Pharmaceuticals Inc’s earnings last quarter?
Currently, no data Available
Is Salarius Pharmaceuticals Inc overvalued?
According to Wall Street analysts Salarius Pharmaceuticals Inc’s price is currently Overvalued.
Does Salarius Pharmaceuticals Inc pay dividends?
Salarius Pharmaceuticals Inc does not currently pay dividends.
What is Salarius Pharmaceuticals Inc’s EPS estimate?
Salarius Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Salarius Pharmaceuticals Inc have?
Salarius Pharmaceuticals Inc has 7,645,594 shares outstanding.
What happened to Salarius Pharmaceuticals Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Salarius Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SLRX
Company Description
Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Technical Analysis
Biodexa Pharmaceuticals
―
TNF Pharmaceuticals
―
Scinai Immunotherapeutics
―
Oragenics
―
Onconetix
―
Ownership Overview
2.84%
Insiders
0.45% Mutual Funds
0.72% Other Institutional Investors
98.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---